Abciximab improves the outcome at six months after stenting

In the EPISTENT trial of 2399 patients, Kaplan-Meier estimates of the incidence of the primary endpoint (death or myocardial infarction) was lower in those treated with abciximab after stenting compared to those undergoing angioplasty with abcixmab therapy (p = 0.01) or stenting with placebo (p <0.001) treatment (5.6, 7.8, and 11.4 percent, respectively).